Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Doxycycline monohydrate
Galderma (UK) Ltd
J01AA02
Doxycycline monohydrate
40mg
Modified-release capsule
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 05010300; GTIN: 5020465200277 5020465200567
_LAUNCHING DEPARTMENT - Z.I. Galderma_ _74540 ALBY-SUR-CHERAN - FRANCE_ DIELINES Artwork approved by: Date: Signature: _40 MG MODIFIED RELEASE HARD CAPSULES_ WHOLE TEXT , including barcodes, pre-printed mentions and legal or special labelling constraints. PLEASE CHECK PROOF CAREFULLY TO ENSURE ALL ELEMENTS ARE CORRECT. Product code: P25883-1 Product description: EFRACEA 40MG Market: GBR Article: Leaflet Flat size: 180x315 Font size: 9 pt Specification n° MT.09.MPS.1893 PMS 432U MT.09.DRA.2375.R00.2 NOTICE EGERKINGEN RECTO 180x315 WHAT IS IN THIS LEAFLET 1. What Efracea is and what it is used for 2. What you need to know before you take Efracea 3. How to take Efracea 4. Possible side effects 5. How to store Efracea 6. Contents of the pack and other information 1. WHAT EFRACEA IS AND WHAT IT IS USED FOR Efracea is a medicine containing the active substance doxycycline. It is used in adults to reduce the pimples or red bumps on the face caused by a condition called rosacea. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE EFRACEA DO NOT TAKE EFRACEA ■ if you are allergic (hypersensitive) to any medicinal product in the tetracycline family, including doxycycline or minocycline, or to any of the other ingredients of this medicine (listed in section 6.) ■ if you are pregnant Efracea should not be used from the 4th month of pregnancy because it may harm the unborn child. If you suspect or learn that you are pregnant whilst taking Efracea, contact your doctor immediately. ■ in combination with retinoids_ (drugs used in the treatment of certain _ _skin disorders such as severe acne)_ administered by the oral route (see section Other medicines and Efracea). ■ if you have a condition causing absence of acid in the stomach (achlorhydria) or if you have had surgery on the upper part of the gut (called the duodenum). Efracea must not be taken by infants or children under the age of 12, because it may cause permanent discolouration of the teeth or problems with tooth development. WARNINGS AND PRECAUTIONS Efracea must not be us Read the complete document
OBJECT 1 EFRACEA 40MG MODIFIED RELEASE HARD CAPSULES Summary of Product Characteristics Updated 16-Nov-2017 | Galderma (U.K) Ltd 1. Name of the medicinal product Efracea 40 mg modified-release hard capsules 2. Qualitative and quantitative composition Each capsule contains 40 mg doxycycline (as monohydrate). Excipients with known effect: 102 – 150 mg of sucrose and 26.6 - 29.4 μg of Allura red AC aluminium lake (E129). For thefull list of excipients, see section 6.1. 3. Pharmaceutical form Modified-release hard capsule Beige capsule, No. 2 size, bear the marking “GLD 40”. 4. Clinical particulars 4.1 Therapeutic indications Efracea is indicated to reduce papulopustular lesions in adult patients with facial rosacea. 4.2 Posology and method of administration Posology _Adults, including older people: _ Oral use. The daily dose is 40 mg (1 capsule). _Patients with renal impairment_ No dosage adjustment is necessary in patients with renal impairment. _Patients with hepatic impairment_ Efracea should be administered with caution to patients with hepatic impairment or to those receiving potentially hepatotoxic medicinal products (see section 4.4) _Paediatric population _ Efracea is contraindicated in children below 12 years of age (see section 4.3). Method of administration THE CAPSULE SHOULD BE TAKEN IN THE MORNING, ON AN EMPTY STOMACH, PREFERABLY AT LEAST ONE HOUR PRIOR TO OR TWO HOURS AFTER THE MEAL. THE CAPSULE SHOULD BE TAKEN WITH ADEQUATE AMOUNTS OF WATER IN ORDER TO REDUCE THE RISK OF OESOPHAGEAL IRRITATION AND ULCERATION (SEE SECTION 4.4). Patients should be evaluated after 6 weeks and, if no effect is seen, consideration should be given to stopping treatment. In clinical trials patients were treated for 16 weeks. Upon discontinuation, lesions tended to reappear at 4 weeks follow-up. Therefore it is recommended that patients should be assessed 4 weeks after stopping treatment. 4.3 Contraindications Hypersensitivity to the active substance, to other tetracyclines or to any of the excipients listed in section Read the complete document